Analysts Issue Forecasts for FDMT Q1 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – HC Wainwright issued their Q1 2025 EPS estimates for shares of 4D Molecular Therapeutics in a report released on Monday, March 3rd. HC Wainwright analyst M. Caufield forecasts that the company will earn ($0.92) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.94) EPS, FY2025 earnings at ($3.72) EPS, FY2026 earnings at ($4.00) EPS, FY2027 earnings at ($4.32) EPS, FY2028 earnings at ($4.07) EPS and FY2029 earnings at ($2.80) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.10).

A number of other research analysts also recently commented on FDMT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, February 19th. Chardan Capital lowered their price target on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday. Morgan Stanley lowered their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a report on Monday, January 13th. Bank of America lowered their price target on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, BMO Capital Markets downgraded shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $40.00 to $15.00 in a report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.38.

4D Molecular Therapeutics Trading Down 0.5 %

Shares of NASDAQ:FDMT opened at $4.14 on Thursday. 4D Molecular Therapeutics has a 12 month low of $3.92 and a 12 month high of $36.25. The company has a 50-day moving average price of $5.08 and a 200 day moving average price of $8.34. The company has a market cap of $191.69 million, a price-to-earnings ratio of -1.45 and a beta of 2.83.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently modified their holdings of FDMT. KLP Kapitalforvaltning AS purchased a new position in shares of 4D Molecular Therapeutics during the fourth quarter worth approximately $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of 4D Molecular Therapeutics during the fourth quarter worth approximately $50,000. PNC Financial Services Group Inc. increased its position in shares of 4D Molecular Therapeutics by 66.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after acquiring an additional 3,630 shares during the period. Daiwa Securities Group Inc. increased its position in shares of 4D Molecular Therapeutics by 5,291.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock worth $55,000 after acquiring an additional 9,737 shares during the period. Finally, Velan Capital Investment Management LP purchased a new position in shares of 4D Molecular Therapeutics during the fourth quarter worth approximately $56,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.